IRIS
Fiorino, Gionata
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.076
AS - Asia 6.130
EU - Europa 2.439
SA - Sud America 1.459
AF - Africa 358
Continente sconosciuto - Info sul continente non disponibili 271
OC - Oceania 25
Totale 21.758
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.808
SG - Singapore 3.655
BR - Brasile 1.185
CN - Cina 961
VN - Vietnam 760
IT - Italia 637
FI - Finlandia 413
IE - Irlanda 276
NG - Nigeria 221
DE - Germania 215
GB - Regno Unito 182
FR - Francia 181
CA - Canada 158
HK - Hong Kong 142
NL - Olanda 112
IN - India 110
SE - Svezia 104
AR - Argentina 102
BD - Bangladesh 70
TR - Turchia 67
RU - Federazione Russa 58
MX - Messico 57
IQ - Iraq 54
EC - Ecuador 50
ID - Indonesia 47
ES - Italia 42
IL - Israele 42
UA - Ucraina 42
ZA - Sudafrica 38
BE - Belgio 37
CO - Colombia 33
JP - Giappone 32
EG - Egitto 26
PY - Paraguay 24
CL - Cile 23
PL - Polonia 22
SA - Arabia Saudita 22
DZ - Algeria 21
PK - Pakistan 21
AU - Australia 20
CZ - Repubblica Ceca 20
VE - Venezuela 20
KZ - Kazakistan 14
MA - Marocco 14
UZ - Uzbekistan 14
IR - Iran 13
LT - Lituania 13
AE - Emirati Arabi Uniti 12
KE - Kenya 12
RO - Romania 12
CR - Costa Rica 11
PE - Perù 11
PH - Filippine 11
PT - Portogallo 11
AZ - Azerbaigian 10
KR - Corea 10
MY - Malesia 10
JM - Giamaica 9
NP - Nepal 9
HN - Honduras 8
SK - Slovacchia (Repubblica Slovacca) 8
TN - Tunisia 8
UY - Uruguay 8
AL - Albania 7
AT - Austria 6
GR - Grecia 6
BB - Barbados 5
DO - Repubblica Dominicana 5
GT - Guatemala 5
JO - Giordania 5
MD - Moldavia 5
QA - Qatar 5
SY - Repubblica araba siriana 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
CH - Svizzera 4
GE - Georgia 4
NI - Nicaragua 4
NO - Norvegia 4
SN - Senegal 4
BN - Brunei Darussalam 3
ET - Etiopia 3
EU - Europa 3
KH - Cambogia 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
BF - Burkina Faso 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
CY - Cipro 2
GA - Gabon 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
OM - Oman 2
Totale 21.469
Salva come PNG Salva come JPEG
Città #
Singapore 1.729
Wilmington 1.554
Chandler 1.238
Ashburn 625
The Dalles 601
San Mateo 587
Dallas 517
Ann Arbor 435
Shanghai 426
Helsinki 410
Council Bluffs 321
Leawood 286
Princeton 281
Ho Chi Minh City 272
Lawrence 271
Dublin 270
Milan 270
San Jose 257
New York 237
Boardman 234
Benin City 220
Beijing 214
Hanoi 169
Fairfield 153
Woodbridge 153
Paris 148
Hong Kong 137
São Paulo 114
Santa Clara 108
Rome 106
Los Angeles 102
Toronto 93
Amsterdam 91
London 75
Buffalo 70
Rio de Janeiro 53
Norwalk 50
Phoenix 48
Seattle 46
Columbus 42
Orem 41
Kocaeli 40
Haiphong 36
Brussels 33
Monmouth Junction 28
San Diego 28
Brasília 27
Chicago 26
Houston 26
Redwood City 26
Da Nang 24
Baghdad 21
Curitiba 21
Guayaquil 21
Munich 20
Frankfurt am Main 19
Miami 19
Belo Horizonte 18
Chennai 18
Figino 18
Johannesburg 18
Naples 18
Tokyo 18
Biên Hòa 17
Bologna 17
Brooklyn 17
Campinas 17
Pune 17
Abbiategrasso 16
Atlanta 16
Cambridge 16
Montreal 16
Falkenstein 15
Brno 14
Hải Dương 14
Porto Alegre 14
Turin 14
Warsaw 14
Cairo 13
Charlotte 13
Ninh Bình 13
Erbil 12
Guarulhos 12
Las Vegas 12
Mexico City 12
Nairobi 12
Sacramento 12
Birmingham 11
Can Tho 11
Des Moines 11
Dhaka 11
Goiânia 11
Jakarta 11
Mansfield 11
Medellín 11
Quito 11
Tashkent 11
Thái Bình 11
Boston 10
Bradenton 10
Totale 14.063
Salva come PNG Salva come JPEG
Nome #
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications 387
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 152
Adalimumab in ulcerative colitis: hypes and hopes 151
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease 135
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis 134
A Prospective Comparison Between 1.5t Magnetic Resonance and 3t Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience 132
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 131
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease 130
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 128
Adalimumab in Crohn's disease : tips and tricks after 5 years of clinical experience 127
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 123
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 123
ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease Part 2. IBD scores and general principles and technical aspects 122
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 118
Risk of postoperative recurrence and postoperative management of Crohn's disease 118
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. 117
Perception of reproductive health in women with inflammatory bowel disease 114
Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps 112
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD 112
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 110
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis 110
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 109
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 108
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 108
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 106
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study 106
‘Quality of care’ standards in inflammatory bowel disease: A systematic review 104
Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study 103
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 103
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease 103
Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial 103
A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis 103
A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY ASSESSING THE EFFECTIVENESS OF BUDESONIDE MMX® FOR MILD-TO-MODERATE ULCERATIVE COLITIS 101
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 100
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 100
Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn's disease: a tertiary centre real-life experience 100
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease 100
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment 99
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 98
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 98
Effect of Immunosuppression on Immune Response to Pneumococcal Vaccine in Inflammatory Bowel Disease: A Prospective Study 98
Are Surgical Rates Decreasing in the Biological Era In IBD? 98
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease : a case-matched analysis 98
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease 97
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 95
A PROLONGED FOLLOW-UP ON THE EFFICACY AND SAFETY OF INFLIXIMAB BIOSIMILAR CT-P13 IN IBD ACROSS ITALY: THE PROSIT COHORT 95
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 94
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis 94
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 92
Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease 92
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling 91
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases 91
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 90
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 90
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 89
Contrast-enhancement at magnetic resonance enterography does not differentiate between fibrosis and inflammation in Crohn's disease: a prospective cohort study 88
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study 88
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 88
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 88
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 88
Adalimumab for the treatment of pediatric Crohn's disease 87
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 87
The Role of Magnetic Resonance Imaging in Detecting Intestinal Fibrosis in Crohn's Disease 87
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? 86
Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience 86
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges 86
Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study 85
Familial aggregation in inflammatory bowel disease: Is it genes or environment? 85
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease 85
STIMULATION OF CYP450-MEDIATED omega-3 DOCOSAHEXAENOIC ACID (DHA) METABOLISM VIA MFSD2A AS A NOVEL THERAPY FOR INFLAMMATORY BOWEL DISEASE 85
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation 84
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target 84
Emerging therapeutic targets and strategies in Crohn's disease 83
The safety of biological pharmacotherapy for the treatment of ulcerative colitis 83
Videocapsule endoscopy in portal hypertension: Seek till you find 83
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study 83
Clinical Utility of the LeMann Index and Rutgeerts Score to Predict Postoperative Course of Crohn's Disease: A Retrospective Single-Center Cohort Study 83
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 82
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 82
JAK inhibitors: Novel developments in management of ulcerative colitis 82
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 82
A HEALTH TECHNOLOGY-RELATED COST DESCRIPTION CONCERNING ITALIAN IBD CENTRES DEALING WITH CROHN'S DISEASE: RESULTS FROM SOLE STUDY 82
MRI in Crohn's disease : current and future clinical applications 81
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation 81
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease 81
VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY AND MODULATES SERUM AND AUTONOMIC BIOMARKERS IN BIOLOGICREFRACTORY CROHN'S DISEASE 81
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biologics 81
Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy 81
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 80
Infliximab Inhibits Mucosal Pathological Angiogenesis in Crohn's Disease 80
y ANTIBODIES TO INFLIXIMAB IN PATIENTS TREATED WITH EITHER THE REFERENCE BIOLOGIC OR THE BIOSIMILAR CT-P13 SHOW IDENTICAL REACTIVITY TOWARDS BIOSIMILARS CT-P13 AND SB2 IN INFLAMMATORY BOWEL DISEASE 80
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 80
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 79
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment 79
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients 79
MRE Findings at Crohn's Disease Diagnosis: Disease Activity, Bowel Damage and Predictive Value for Long-Term Outcomes 79
Hyaluronan Accelerates Intestinal Mucosal Healing through Interaction with TSG-6 78
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target 76
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 76
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile 76
Totale 9.962
Salva come PNG Salva come JPEG
Categoria #
all - tutte 147.239
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.239
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.409 0 15 65 304 12 8 64 196 152 203 308 82
2022/20233.327 612 152 386 349 205 279 16 253 541 321 168 45
2023/20241.918 202 148 382 92 56 252 101 117 34 41 167 326
2024/20252.695 60 61 25 55 29 323 127 300 349 738 294 334
2025/20268.040 1.036 547 720 1.032 286 249 1.946 440 406 448 266 664
2026/20271.294 727 567 0 0 0 0 0 0 0 0 0 0
Totale 21.758